Brief: Herantis Pharma Provides Update On Timeline For Ongoing Phase 1-2 CDNF Trial

Herantis Pharma Oyj

26/09/2019 08:19

Sept 26 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * REG-HERANTIS PHARMA PLC PROVIDES UPDATE ON TIMELINE FOR
ONGOING
PHASE 1-2 CDNF TRIAL
    * THEREFORE, COMPANY IS UPDATING GUIDANCE ON ANNOUNCEMENT OF
STUDY'S TOPLINE DATA FROM LAST QUARTER OF 2019 TO Q1 OF 2020
    * TRIAL CONTINUES TO PROCEED AS ANTICIPATED AND ITS FIRST
PHASE IS
EXPECTED TO REACH COMPLETION OF PATIENT VISITS IN LAST QUARTER
OF 2019 IN LINE WITH PREVIOUSLY COMMUNICATED TIMELINES
    * COMPILATION AND ANALYSIS OF DATA FOR UNBLINDING OF STUDY
MAY
TAKE UNTIL Q1 OF 2020

Source text for Eikon:  ID:nGNE4nXfww 
Further company coverage:  HRTIS.HE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))